# Build a Type 2 Diabetes Risk Screening App with Ovok in 30 Minutes

Canonical page: https://docs.ovok.com/guides/type-2-diabetes

Build a small patient app that stores a validated FINDRISC assessment as a FHIR `QuestionnaireResponse` and saves TeleBGM Gen1 BLE readings as FHIR-backed blood-glucose Observations. It uses the current `@ovok/native` and `@ovok/core` APIs.

The “30 minutes” is a guided implementation target for an engineer with an Expo environment and an approved questionnaire resource already available. Native builds, Console setup, BLE pairing, and clinical content review will take longer.

## What you will build [#what-you-will-build]

- Patient registration and sign-in for an Ovok sandbox project.
- An approved FINDRISC Questionnaire rendered with `QuestionnaireForm`.
- A locally calculated score using the questionnaire’s reviewed version and an explicit scoring map. Ovok does not currently provide a FINDRISC scoring operation.
- Optional standard FHIR questionnaire extraction only when the approved Questionnaire is configured for it.
- TeleBGM Gen1 BLE discovery and a normalized blood-glucose measurement saved with `ovok.measurements.save()`.
- Separate assessment and glucose histories, localized through Ovok CMS.

```mermaid
flowchart LR
  patient[Patient] --> questionnaire[FHIR Questionnaire]
  questionnaire --> answers[FHIR QuestionnaireResponse]
  answers --> score[Reviewed FINDRISC scoring in app]
  meter[TeleBGM Gen1 BLE] --> native[Ovok Native Bluetooth]
  native --> observation[Ovok blood-glucose measurement API]
  observation --> fhir[FHIR Observation]
  answers --> history[Patient screening history]
  fhir --> history
```

## Clinical and content boundary [#clinical-and-content-boundary]

FINDRISC is a risk-screening instrument, not a diagnosis. A blood-glucose reading is a measurement; this tutorial does not interpret it as diabetes, combine it with FINDRISC into a new score, or give treatment advice. The published Finnish Diabetes Association guidance says its risk result is not a diagnosis and does not replace a health professional’s assessment. See its [use instructions and sources](https://diabetes.fi/lahteet-ja-kayttoohjeet-kansansairauksien-riskitesti/) and the [original Diabetes Risk Score paper](https://doi.org/10.2337/diacare.26.3.725).

The guide does **not** reproduce FINDRISC question text, answer labels, or a translated instrument. Before deploying, obtain the exact questionnaire and any required permissions, attribution, and validated translations from an authorized source. Have the responsible clinical owner confirm the instrument version, answer order, scoring map, and result wording. The app must fail closed if the installed Questionnaire version is not the reviewed version.

## Before you start [#before-you-start]

- Node.js, Expo tooling, Xcode and/or Android Studio.
- A physical iOS or Android device for Bluetooth tests. Expo Go cannot run the BLE native module.
- Access to the Ovok Console and a sandbox project.
- The approved FHIR `Questionnaire` for the classic eight-item FINDRISC version, already published to the sandbox project. The newer nine-question Finnish risk-test flow is a different instrument and must not be substituted into the eight-item score mapping.
- A TeleBGM Gen1 BLE meter and compatible test strips. Use synthetic patient data in the sandbox.

The current Sandbox CapabilityStatement advertises standard CRUD/search for `Questionnaire`, `QuestionnaireResponse`, and `Observation`, plus the `Questionnaire/$populate` and `QuestionnaireResponse/$extract` operations. Confirm against the live [FHIR R4 CapabilityStatement](/api/fhir/r4/capability-statement) for the project you use.

## Build the app [#build-the-app]

| Step | Page | Result |
| --- | --- | --- |
| 1 | [Create the React Native app](/guides/type-2-diabetes/create-the-react-native-app) | Expo Router project with native build and BLE dependencies |
| 2 | [Create and configure the Ovok project](/guides/type-2-diabetes/create-and-configure-the-ovok-project) | Least-privilege sandbox patient workflow |
| 3 | [Configure localisation](/guides/type-2-diabetes/configure-localisation) | i18next reads published UI copy from Ovok CMS |
| 4 | [Choose the glucose device](/guides/type-2-diabetes/choose-the-glucose-device) | TeleBGM Gen1 BLE allowlist uses `IntegratedDevices.BGM` |
| 5 | [Add the FINDRISC Questionnaire](/guides/type-2-diabetes/add-the-findrisc-questionnaire) | Version-checked questionnaire and tested score mapping |
| 6 | [Initialise Ovok, auth, and Bluetooth](/guides/type-2-diabetes/initialise-ovok-auth-and-bluetooth) | One client, authenticated Patient routes, one BLE runtime |
| 7 | [Build the screening home](/guides/type-2-diabetes/build-the-screening-home) | Patient can complete and save the questionnaire |
| 8 | [Connect TeleBGM and save readings](/guides/type-2-diabetes/connect-telebgm-and-save-readings) | Pair device and save glucose readings as Observations |
| 9 | [Build results and history](/guides/type-2-diabetes/build-results-and-history) | Distinct FINDRISC and glucose history views |
| 10 | [Settings, localisation, and validation](/guides/type-2-diabetes/settings-localisation-and-validation) | CMS-backed UI, language preference, and sandbox journey checks |

## Canonical references [#canonical-references]

- [React Native SDK installation](/native-sdk/guide/how-to/installation), [authentication](/native-sdk/guide/modules/auth), [Bluetooth](/native-sdk/guide/modules/bt-management), and [supported devices](/native-sdk/guide/supported-devices).
- [`Questionnaire`](/api/fhir/r4/questionnaire), [`QuestionnaireResponse`](/api/fhir/r4/questionnaire-response), [`$populate`](/primitives/populate-questionnaire), and [`$extract`](/primitives/extract-observations).
- [Project setup](/authentication/project-setup), [patient registration](/authentication/patient-registration), and [Access Policies](/access-policies).
- [Blood-glucose measurements](/web-sdk/core/measurements/blood-glucose) and [`ovok.measurements`](/web-sdk/core/namespaces/measurements).
- [Use Ovok CMS with i18n](/cms/use-ovok-cms-with-i18n).
